111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
多组学孟德尔随机化识别出干燥综合征的治疗靶点，并通过临床和贝叶斯验证
Authors He J, Li K, Guo Z, Zhou X, Tang X
Received 29 May 2025
Accepted for publication 11 November 2025
Published 27 November 2025 Volume 2025:18 Pages 16685—16698
DOI https://doi.org/10.2147/JIR.S543644
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Ning Quan
Jiale He, Kesong Li, Zilin Guo, Xinyao Zhou, Xiaopo Tang
Department of Rheumatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People’s Republic of China
Correspondence: Xinyao Zhou, Email xyz_1102@126.com Xiaopo Tang, Email tangxiaopo@163.com
Background: There are currently no effective pharmacological treatments for Sjögren’s disease (SjD). Our study aims to identify potential therapeutic targets for the condition using druggable genome-wide Mendelian randomization (MR).
Methods: Druggable genome data were obtained from the Drug-Gene Interaction Database (DGIdb) and the study by Finan et al. We then integrated these druggable genes with blood-derived cis-eQTL, cis-mQTL, and cis-pQTL datasets, each analyzed separately in two-sample MR analyses using SjD GWAS summary statistics as the outcome, applying a genome-wide MR approach focused on druggable targets. Bayesian colocalization was applied to validate shared causal genetic variants. Protein levels of prioritized genes were validated in clinical serum samples from SjD patients and controls using ELISA. Phenome-wide MR (Phe-MR) analysis was conducted across 1359 phenotypes from the UK Biobank to evaluate potential pleiotropic effects and safety profiles of the identified targets, assessed side effects and alternative indications of identified targets.
Results: Fourteen druggable genes were identified, with eight (PLAT, SIRPB1, LAIR2, NEU1, SLC22A16, RAD52, PSPH, and CDH23) demonstrating consistent causal relationships with SjD. ELISA validation supported differential protein expression for these targets. Key findings include the protective role of NEU1 and PSPH in systemic immune regulation, the pathogenic impact of PLAT, SIRPB1, BRD2, and LAIR2 on inflammation, and the potential involvement of SLC22A16 and RAD52 in metabolic stress and immune activation. Existing pharmacological compounds targeting these genes, including Aminocaproic acid, Resveratrol, Levocarnitine, Imatinib, and Zinc chloride were identified as potential therapeutic candidates. No significant adverse effects were detected through Phe-MR analysis.
Conclusion: Our research indicated PLAT, SIRPB1, LAIR2, NEU1, SLC22A16, RAD52, PSPH, and CDH23 may serve as promising targets for SjD, while the effectiveness of Aminocaproic acid, Resveratrol, Levocarnitine, Imatinib, and Zinc chloride for SjD requires further validation.
Keywords: Sjögren’s disease, Mendelian randomization, druggable genome, Bayesian colocalization, therapeutic targets, Phe-MR analysis
Department of Rheumatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People’s Republic of China
Correspondence: Xinyao Zhou, Email xyz_1102@126.com Xiaopo Tang, Email tangxiaopo@163.com
Background: There are currently no effective pharmacological treatments for Sjögren’s disease (SjD). Our study aims to identify potential therapeutic targets for the condition using druggable genome-wide Mendelian randomization (MR).
Methods: Druggable genome data were obtained from the Drug-Gene Interaction Database (DGIdb) and the study by Finan et al. We then integrated these druggable genes with blood-derived cis-eQTL, cis-mQTL, and cis-pQTL datasets, each analyzed separately in two-sample MR analyses using SjD GWAS summary statistics as the outcome, applying a genome-wide MR approach focused on druggable targets. Bayesian colocalization was applied to validate shared causal genetic variants. Protein levels of prioritized genes were validated in clinical serum samples from SjD patients and controls using ELISA. Phenome-wide MR (Phe-MR) analysis was conducted across 1359 phenotypes from the UK Biobank to evaluate potential pleiotropic effects and safety profiles of the identified targets, assessed side effects and alternative indications of identified targets.
Results: Fourteen druggable genes were identified, with eight (PLAT, SIRPB1, LAIR2, NEU1, SLC22A16, RAD52, PSPH, and CDH23) demonstrating consistent causal relationships with SjD. ELISA validation supported differential protein expression for these targets. Key findings include the protective role of NEU1 and PSPH in systemic immune regulation, the pathogenic impact of PLAT, SIRPB1, BRD2, and LAIR2 on inflammation, and the potential involvement of SLC22A16 and RAD52 in metabolic stress and immune activation. Existing pharmacological compounds targeting these genes, including Aminocaproic acid, Resveratrol, Levocarnitine, Imatinib, and Zinc chloride were identified as potential therapeutic candidates. No significant adverse effects were detected through Phe-MR analysis.
Conclusion: Our research indicated PLAT, SIRPB1, LAIR2, NEU1, SLC22A16, RAD52, PSPH, and CDH23 may serve as promising targets for SjD, while the effectiveness of Aminocaproic acid, Resveratrol, Levocarnitine, Imatinib, and Zinc chloride for SjD requires further validation.
Keywords: Sjögren’s disease, Mendelian randomization, druggable genome, Bayesian colocalization, therapeutic targets, Phe-MR analysis